Group 1 - The company, Hualan Biological Engineering Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of its "lyophilized type b Haemophilus influenzae conjugate vaccine" [1] - The vaccine aims to prevent invasive infections caused by type b Haemophilus influenzae, including meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [2] - The Hib vaccine is developed using purified Hib capsular polysaccharide combined with tetanus toxoid protein, and it is expected to induce an immune response against Hib [2] Group 2 - The company is also developing a combination vaccine based on the DTP (diphtheria, tetanus, and pertussis) vaccine, with the Hib vaccine as one of its components [2] - Following the approval of the clinical trial, the company must conduct clinical trials and obtain further approval from the National Medical Products Administration before the vaccine can be marketed [3] - The drug development process is lengthy and involves multiple stages, which may be affected by uncertainties [3]

Core Viewpoint - The company has received approval for clinical trials of its "lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine," which is aimed at preventing invasive infections caused by Hib bacteria [1][2]. Group 1: Clinical Trial Approval - The company's subsidiary, Hualan Biological Vaccine Co., Ltd., has obtained the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for the Hib vaccine [1]. - The clinical trial application for the vaccine was accepted on May 21, 2025, and has met the requirements for drug registration [1]. - The vaccine is intended to prevent invasive infections such as meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis caused by Hib [1]. Group 2: Vaccine Development - The Hib vaccine is developed using purified Hib capsular polysaccharide combined with tetanus toxoid protein, and it is in a lyophilized form [2]. - The vaccine is expected to induce an immune response against Hib, providing protection to the vaccinated individuals [2]. - The company is also developing a combination vaccine based on the DTP (diphtheria, tetanus, and pertussis) framework, with the Hib vaccine as one of its components [2].

（文章来源：证券日报） 证券日报网讯 8月13日晚间，华兰疫苗发布关于部分首次公开发行前已发行股份上市流通的提示性公告 称，本次上市流通的限售股为公司部分首次公开发行前已发行股份；本次解除限售股东户数共计2户， 为华兰生物工程股份有限公司和科康有限公司，解除限售的股份数量共计459，000，000股，占公司总 股本的76.37%。本次解除限售的股份上市流通日期为2025年8月18日（星期一）。 ...

Core Points - The company Hualan Biological announced the approval of a clinical trial for its "lyophilized Haemophilus influenzae type b conjugate vaccine" by the National Medical Products Administration [2] - The clinical trial aims to prevent invasive infections caused by Haemophilus influenzae type b, including meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [2] - The approval was granted following the review of the application submitted on May 21, 2025, confirming that it meets the requirements for drug registration [2] Summary by Categories Company Developments - Hualan Biological's subsidiary, Hualan Biological Vaccine Co., Ltd., received a clinical trial approval notification for its vaccine [2] - The company is expected to commence the clinical trial work promptly in accordance with the approval notification [2] Industry Implications - The approval of the vaccine is significant for addressing public health concerns related to invasive infections caused by Haemophilus influenzae type b [2] - This development may enhance the company's position in the vaccine market and contribute to advancements in preventive healthcare [2]

Core Viewpoint - Huashan Biological Vaccine Co., Ltd. is preparing for the public offering of its A-shares on the ChiNext board, with specific commitments made by its controlling shareholders regarding share lock-up and trading practices [1][11][19]. Summary by Sections Initial Public Offering Overview - The company plans to issue 40,010,000 shares, increasing its total share capital from 360,000,000 to 400,010,000 shares as of February 18, 2022 [1]. - Following a stock split of 10 shares for every 5 shares, the total share capital will rise to 600,015,000 shares [2]. Share Lock-up and Release - As of the date of the verification opinion, the total share capital stands at 601,027,500 shares, with 141,648,150 shares (23.57%) being unrestricted and 459,000,000 shares (76.37%) subject to lock-up [2][20]. - The lock-up period for the shares is extended by 6 months due to specific conditions being triggered, with the release date set for August 18, 2025 [2][3]. Commitments by Shareholders - The controlling shareholders, Huashan Biological and Hong Kong Kexin, have made commitments regarding the non-transfer of shares during the initial 36 months post-listing and conditions under which the lock-up period may be extended [3][4]. - Shareholders are obligated to comply with regulations regarding share reduction and must avoid any actions that could harm the interests of other shareholders [15][16]. Corporate Governance and Compliance - The company has established measures to ensure compliance with laws and regulations, including maintaining the independence of its operations and avoiding conflicts of interest with its controlling shareholders [14][19]. - The commitments made by the controlling shareholders are legally binding and will remain effective as long as they hold shares in the company [18][19]. Financial and Operational Commitments - The company has outlined a profit distribution policy and commitments to ensure that shareholder returns are met following the public offering [19][20]. - Measures are in place to stabilize the stock price and protect the interests of minority investors, including potential buyback plans if stock prices fall below certain thresholds [11][12].

经深圳证券交易所《关于华兰生物疫苗股份有限公司人民币普通股股票在创业 板上市的通知》（深证上[2022]154 号）同意，华兰生物疫苗股份有限公司（以下简 称"公司"或"华兰疫苗"）首次公开发行人民币普通股（A 股）股票 40,010,000 股， 并于 2022 年 2 月 18 日在深圳证券交易所创业板上市交易。公司首次公开发行股票 前总股本为 360,000,000 股，首次公开发行完成后，公司总股本为 400,010,000 股。 每 10 股转增 5 股，共计 200,005,000 股，转增后公司总股本由 400,010,000 股变为 一个归属期归属的 1,012,500 股股份上市流通，公司总股本由 600,015,000 股变为 截至本公告披露日，公司总股本为 601,027,500 股，其中无限售条件流通股为 占总股本的比例为 76.43%。 证券代码：301207 证券简称：华兰疫苗 公告编号：2025-035 华兰生物疫苗股份有限公司 关于部分首次公开发行前已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

Core Viewpoint - The approval of the clinical trial for the freeze-dried Hib vaccine marks a significant milestone for the company, enhancing its product portfolio and supporting its strategic development in the vaccine sector [1] Group 1: Clinical Trial Approval - The company received the clinical trial approval notice from the National Medical Products Administration for the freeze-dried Hib vaccine [1] - The approval indicates that the Hib vaccine meets the requirements for drug registration and allows for clinical trials aimed at preventing invasive infections caused by Hib, including meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [1] Group 2: Strategic Significance - The approval of the freeze-dried Hib vaccine is seen as a successful step in the company's product research and development strategy [1] - This development not only enriches the company's product lineup but also represents an important move towards achieving multi-valent products [1] - The approval is expected to strengthen the company's position in the domestic second-class vaccine market and contribute to the sustainable development of its vaccine business [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its lyophilized Haemophilus influenzae type b conjugate vaccine, indicating progress in its vaccine development pipeline [1] Group 1: Company Developments - The company's subsidiary, Hualan Biological Vaccine Co., Ltd., has been granted a clinical trial approval notice for the lyophilized Haemophilus influenzae type b conjugate vaccine [1] - The clinical trial application was accepted on May 21, 2025, and meets the requirements for drug registration [1] - The vaccine aims to prevent invasive infections caused by Haemophilus influenzae type b, including meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [1]

Core Viewpoint - Hualan Biological's subsidiary has received approval for a clinical trial of a new vaccine, indicating progress in its vaccine development pipeline [2] Group 1: Company Announcement - Hualan Biological announced on August 13 that its subsidiary, Hualan Biological Vaccine Co., Ltd., received a clinical trial approval notice from the National Medical Products Administration [2] - The approved clinical trial is for a "lyophilized type b Haemophilus influenzae conjugate vaccine" [2]

格隆汇8月13日丨华兰生物(002007.SZ)公布，2025年8月12日，华兰生物工程股份有限公司控股子公司 华兰生物疫苗股份有限公司(以下称"疫苗公司")收到国家药品监督管理局下发的《药物临床试验批准通 知书》(通知书编号：2025LP02051)，由疫苗公司申报的"冻干b型流感嗜血杆菌结合疫苗"临床试验申请 获得批准：经审查，2025年5月21日受理的冻干b型流感嗜血杆菌结合疫苗符合药品注册的有关要求，同 意开展预防由b型流感嗜血杆菌引起的侵袭性感染(包括脑膜炎、肺炎、败血症、蜂窝织炎、关节炎、会 厌炎等)的临床试验。疫苗公司将按照药物临床试验批准通知书的要求，尽快开展相关临床试验工作。 疫苗公司研发的Hib疫苗系以纯化的Hib荚膜多糖与破伤风类毒素蛋白结合而成，采用冻干剂型，预期可 在接种后诱导针对Hib的免疫答应，对接种者提供保护作用。此外，疫苗公司正在研发以组分百白破为 基础的联合疫苗，Hib疫苗为其中的组成部分，作为未获批上市的单苗需累积一定的临床数据，完成Hib 单价疫苗的申报上市，并支持未来以组分百白破为基础的联合疫苗的注册申报。 ...